Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRAP-6 (Thrombin Receptor Activating Peptide 6) is a synthetic hexapeptide with the amino acid sequence Ser-Phe-Leu-Leu-Arg-Asn (SFLLRN). It functions as a potent and selective agonist for the Proteinase-Activated Receptor 1 (PAR1), a G protein-coupled receptor that is typically activated by thrombin. TRAP-6 works by mimicking the new N-terminal "tethered ligand" that is exposed when thrombin cleaves the PAR1 receptor. Because it does not require enzymatic cleavage to activate the receptor, it is a valuable pharmacological tool in research for investigating PAR1-mediated pathways in platelet aggregation, inflammation, and pain signaling. In clinical diagnostics, TRAP-6 is utilized in ex vivo platelet function assays, such as the Multiplate TRAPtest, to assess the responsiveness of the PAR1 pathway. Recent research has also highlighted its role in mediating visceral pain and nociceptor activation in models of colitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thrombin receptor-activating peptide 6.